{"created":"2020-08-30T20:03:14.187822+00:00","id":3157,"links":{},"metadata":{"_buckets":{"deposit":"b2e3d66a-3ba8-42d3-bda5-bc593836c3ac"},"_deposit":{"id":"3157","owners":[],"pid":{"revision_id":0,"type":"recid","value":"3157"},"status":"published"},"_oai":{"id":"oai:meral.edu.mm:recid/3157","sets":["1582963366982:1596631759527"]},"communities":["um1"],"item_1583103067471":{"attribute_name":"Title","attribute_value_mlt":[{"subitem_1551255647225":"Effect of GSTP1 polymorphism on efficacy and safety of cyclophosphamide aggressive therapy in lupus nephropathy patients","subitem_1551255648112":""}]},"item_1583103085720":{"attribute_name":"Description","attribute_value_mlt":[{"interim":"

Background Lupus nephritis (LN) occurs in up to 60% of adults with systemic lupus erythematosus (SLE) and is a predictor
\nof poor survival. Cyclophosphamide (CYC) is regarded as the most effective immunosuppressive medication to improve
\nsurvival for patients with LN.
\nObjective This prospective hospital-based study was conducted to identify the effect of glutathione S transferase Pi-1
\n(GSTP1) genotypes on the efficacy and safety of CYC aggressive therapy.
\nMethods We enrolled SLE nephropathy patients admitted to the Department of Rheumatology of the 500-bed Yangon
\nSpecialty Hospital (YSH), Yangon, Myanmar, who received CYC aggressive therapy for 6 months according to treatment
\nguidelines for SLE patients with renal involvement. The frequencies of I/I, I/V and V/V GSTP1 genotypes were determined
\nusing the polymerase chain reaction-restriction fragment length polymorphism method. The efficacy of CYC aggressive
\ntherapy between LN patients with wild GSTP1 (I/I) and those with polymorphic GSTP1 (I/V or V/V) genotypes was evaluated
\nby comparing 24-h urinary protein levels and assessing the remission rates at 3 and 6 months after initiation of CYC.
\nCYC-related myelotoxicity was assessed by reviewing complete blood picture results on the 10th day after CYC treatment.
\nResults In total, 95 eligible patients were recruited. The frequencies of I/I, I/V and V/V GSTP1 genotypes were 54.7, 41.1
\nand 4.2%, respectively. At 3 and 6 months after CYC treatment, mean 24-h urinary protein had significantly decreased from
\nbaseline in both wild and polymorphic genotype groups (p < 0.001). No significant differences were seen between the wild
\nand polymorphic genotype groups with regard to changes in 24-h urinary protein levels, remission at 3 and 6 months or
\nmyelotoxicity.
\nConclusion CYC aggressive therapy had similar efficacy and caused no significant differences in myelotoxicity in wild GSTP1
\n(I/I) and polymorphic GSTP1 (I/V or V/V) genotypes in patients treated according to YSH guidelines for SLE patients with
\nrenal involvement.

"}]},"item_1583103108160":{"attribute_name":"Keywords","attribute_value":[]},"item_1583103120197":{"attribute_name":"Files","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_access","date":[{"dateType":"Available","dateValue":"2019-11-18"}],"displaytype":"preview","filename":"thu2019.pdf","filesize":[{"value":"746 Kb"}],"format":"application/pdf","licensetype":"license_0","mimetype":"application/pdf","url":{"url":"https://meral.edu.mm/record/3157/files/thu2019.pdf"},"version_id":"fce00ab7-7c13-4ffc-bd84-44dc55095d75"}]},"item_1583103131163":{"attribute_name":"Journal articles","attribute_value_mlt":[{"subitem_issue":"","subitem_journal_title":"Drugs & Therapy Perspectives","subitem_pages":"334-340","subitem_volume":"35"}]},"item_1583103147082":{"attribute_name":"Conference papers","attribute_value_mlt":[{"subitem_acronym":"","subitem_c_date":"","subitem_conference_title":"","subitem_part":"","subitem_place":"","subitem_session":"","subitem_website":""}]},"item_1583103211336":{"attribute_name":"Books/reports/chapters","attribute_value_mlt":[{"subitem_book_title":"","subitem_isbn":"","subitem_pages":"","subitem_place":"","subitem_publisher":""}]},"item_1583103233624":{"attribute_name":"Thesis/dissertations","attribute_value_mlt":[{"subitem_awarding_university":"","subitem_supervisor(s)":[{"subitem_supervisor":""}]}]},"item_1583105942107":{"attribute_name":"Authors","attribute_value_mlt":[{"subitem_authors":[{"subitem_authors_fullname":"K. Khine Thu"},{"subitem_authors_fullname":"Aye Aye Lwin"},{"subitem_authors_fullname":"Khin Than maw"},{"subitem_authors_fullname":"Lei Lei Htay"},{"subitem_authors_fullname":"Khin Mar Myint"},{"subitem_authors_fullname":"Myat Myat Soe"},{"subitem_authors_fullname":"Ye Htut Linn"},{"subitem_authors_fullname":"Chit Soe"},{"subitem_authors_fullname":"Nang Hla Hla Win"}]}]},"item_1583108359239":{"attribute_name":"Upload type","attribute_value_mlt":[{"interim":"Publication"}]},"item_1583108428133":{"attribute_name":"Publication type","attribute_value_mlt":[{"interim":"Journal article"}]},"item_1583159729339":{"attribute_name":"Publication date","attribute_value":"2019-11-18"},"item_1583159847033":{"attribute_name":"Identifier","attribute_value":"10.5281/zenodo.3545674"},"item_title":"Effect of GSTP1 polymorphism on efficacy and safety of cyclophosphamide aggressive therapy in lupus nephropathy patients","item_type_id":"21","owner":"1","path":["1596631759527"],"publish_date":"2019-11-18","publish_status":"0","recid":"3157","relation_version_is_last":true,"title":["Effect of GSTP1 polymorphism on efficacy and safety of cyclophosphamide aggressive therapy in lupus nephropathy patients"],"weko_creator_id":"1","weko_shared_id":-1},"updated":"2021-12-13T06:42:21.042721+00:00"}